(Q33371225)

English

Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

object named as

Ann-Lii Cheng

3

0 references

author name string

Hui-Ju Ch'ang

1

1 reference

Europe PubMed Central

26 July 2017

Chuan-Cheng Wang

2

1 reference

Europe PubMed Central

26 July 2017

Chiun Hsu

4

1 reference

Europe PubMed Central

26 July 2017

Yen-Shen Lu

5

1 reference

Europe PubMed Central

26 July 2017

Ming-Chu Chang

6

1 reference

Europe PubMed Central

26 July 2017

Jaw-Town Lin

7

1 reference

Europe PubMed Central

26 July 2017

Hsiu-Po Wang

8

1 reference

Europe PubMed Central

26 July 2017

Her-Shyong Shiah

9

1 reference

Europe PubMed Central

26 July 2017

Tsang-Wu Liu

10

1 reference

Europe PubMed Central

26 July 2017

Jang-Yang Chang

11

1 reference

Europe PubMed Central

26 July 2017

Jacqueline Whang-Peng

12

1 reference

Europe PubMed Central

26 July 2017

Li-Tzong Chen

13

1 reference

Europe PubMed Central

26 July 2017

publication date

1 May 2006

1 reference

Europe PubMed Central

26 July 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

26 July 2017

21

1 reference

Europe PubMed Central

26 July 2017

5

1 reference

Europe PubMed Central

26 July 2017

874-879

1 reference

Europe PubMed Central

26 July 2017

Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04022.X

21 January 2018

Identifiers

10.1111/J.1440-1746.2005.04022.X

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33371225&oldid=1967301265"